n vitro, acetaminophen elicites a 4.4-fold selectivity toward COX-2 inhibition (IC50 113.7 μM for COX-1; IC50 25.8 μM for COX-2). Following oral administration of the drug, maximal ex vivo inhibitions are 56% (COX-1) and 83% (COX-2). Acetaminophen plasma concentrations remaine above the in vitro IC50 for COX-2 for at least 5 h postadministration. Ex vivo IC50 values (COX-1: 105.2 μM; COX-2: 26.3 μM) of acetaminophen compared favorably with its in vitro IC50 values. In contrast to previous concepts, acetaminophen inhibited COX-2 by more than 80%, i.e., to a degree comparable to nonsteroidal antiinflammatory drugs (NSAIDs) and selective COX-2 inhibitors. However, a >95% COX-1 blockade relevant for suppression of platelet function is not achieved[1]. MTT assay shows that Acetaminophen (APAP) in a dose of 50 mM significantly (p<0.001) reduces cell viability to 61.5±6.65%. Interestingly, the significant (p<0.01) increase in cell viability to 79.7±2.47% is observed in the Acetaminophen/HV110 co-treated cells, compared to Acetaminophen treated cells[2].
Administering Acetaminophen (250 mg/kg, orally) to the mice causes significant (p<0.001) liver damage and necrosis of cells as evidenced by the elevated serum hepatic enzymes alanine aminotransferase (ALT), aminotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transferase (γGT) compared with normal group. Conversely, effects of pretreatment with different doses of citral (125, 250, and 500 mg/kg) exhibited a significant (p<0.05) decrease in serum activities of ALT (91.79%, 93.07%, and 95.61%, resp.), AST (93.40%, 91.89%, and 96.52%, resp.), ALP (39.29%, 37.07%, and 59.80%, resp.), and γGT (92.83%, 91.59%, and 93.0%, resp.), when compared to the Acetaminophen group. Similar results were found in pretreatment with SLM on the activity of ALT (95.90%), AST (95.03%), ALP (70.52%), and γGT (92.69%)[3].
对乙酰氨基酚(扑热息痛)是一种选择性环氧化酶-2(COX-2)抑制剂,IC50为25.8 μM,是一种广泛使用的退热镇痛药物。 体外实验表明,对乙酰氨基酚对COX-2具有4.4倍的选择性抑制作用(COX-1的IC50为113.7 μM,COX-2的IC50为25.8 μM)。给药后,药物的最大外体抑制作用分别为56%(COX-1)和83%(COX-2)。对乙酰氨基酚血浆浓度在给药后至少5小时保持高于体外COX-2的IC50。外体IC50值(COX-1: 105.2 μM;COX-2: 26.3 μM)与对乙酰氨基酚的体外IC50值相比具有优越性。与以往概念相反,对乙酰氨基酚抑制COX-2的程度超过80%,即可与非甾体类抗炎药(NSAIDs)和选择性COX-2抑制剂相媲美。然而,对于抑制血小板功能的> 95% COX-1阻断没有达到[1]。 MTT试验显示,以50 mM的剂量给予对乙酰氨基酚(APAP)显著(p<0.001)降低细胞存活率至61.5±6.65%。有趣的是,在对乙酰氨基酚/ HV110联合处理的细胞中,相对于对乙酰氨基酚处理的细胞,细胞存活率显著增加至79.7±2.47%[2]。
将Acetaminophen(口服250mg/kg)给小鼠造成明显的(p<0.001)肝损伤和细胞坏死,表现为血清肝酶丙氨酸转移酶(ALT)、氨基转移酶(AST)、碱性磷酸酶(ALP)和γ-谷氨酰转移酶(γGT)水平升高,与正常组相比。相反,不同剂量的香茅醛(125、250和500 mg/kg)预处理对ALT(91.79%、93.07%和95.61%)、AST(93.40%、91.89%和96.52%)、ALP(39.29%、37.07%和59.80%)和γGT(92.83%、91.59%和93.0%)的血清活性都有显著(p<0.05)降低,与Acetaminophen组相比。与此类似的结果也发现在预处理SLM的ALT(95.90%)、AST(95.03%)、ALP(70.52%)和γGT(92.69%)的活性上。
Reference:
[1]. Hinz, B, et al. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J, 2008. 22(2): p. 383-90.
[2]. Dini? M, et al. Lactobacillus fermentum Postbiotic-induced Autophagy as Potential Approach for Treatment ofAcetaminophen Hepatotoxicity. Front Microbiol. 2017 Apr 6;8:594.
[3]. Uchida NS, et al. Hepatoprotective Effect of Citral on Acetaminophen-Induced Liver Toxicity in Mice. Evid Based Complement Alternat Med. 2017;2017:1796209.
















